author-photo

Jens Peter Volkmer

Stanford University

69

Papers

5028

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.

2021 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (5)
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

2020 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (69)
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (27)
Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (31)
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS: S878

2019
Show All
- Source
- Cite
- Save
Citations (3)
CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (31)
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS: S867

2019
Show All
- Source
- Cite
- Save
Citations (0)